tiprankstipranks
Advertisement
Advertisement
Sutro Biopharma initiated with an Overweight at Barclays
PremiumThe FlySutro Biopharma initiated with an Overweight at Barclays
3M ago
Analyst Reiterates Buy on Sutro Biopharma, Maintains $54 Price Target on Differentiated ADC Platform and Pipeline Progress
Premium
Ratings
Analyst Reiterates Buy on Sutro Biopharma, Maintains $54 Price Target on Differentiated ADC Platform and Pipeline Progress
4M ago
Sutro Biopharma price target raised to $10 from $9 at BofA
Premium
The Fly
Sutro Biopharma price target raised to $10 from $9 at BofA
4M ago
Sutro Biopharma price target raised to $43 from $38 at Leerink
PremiumThe FlySutro Biopharma price target raised to $43 from $38 at Leerink
4M ago
Analyst Reiterates Buy on Sutro Biopharma, Citing STRO-004 Phase I Readout and Broader ADC Platform Potential
Premium
Ratings
Analyst Reiterates Buy on Sutro Biopharma, Citing STRO-004 Phase I Readout and Broader ADC Platform Potential
4M ago
Sutro Biopharma reports Q1 EPS ($2.94), consensus ($3.21)
Premium
The Fly
Sutro Biopharma reports Q1 EPS ($2.94), consensus ($3.21)
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100